Interferon Therapy for Chronic Hepatitis B

Clinics in Liver Disease

Volumn 11, Issue 4, 2007, Pages 839-849

  Asselah, Tarik ^a   Lada, Olivier ^a   Moucari, Rami ^a   Martinot, Michèle ^a   Boyer, Nathalie ^a   Marcellin, Patrick ^a  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; MEMBRANE ANTIGEN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; VIRUS DNA;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISEASE SEVERITY; DNA SYNTHESIS; DRUG EFFICACY; DRUG MECHANISM; HEPATITIS B; HUMAN; IMMUNE RESPONSE; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REVIEW; SEROCONVERSION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B;

EID: 35648945243     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.08.010     Document Type: Review

References (26)

1. Hoofnagle J.H., Doo E., Liang T.J., et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45 4 (2007) 1056-1075
2. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 2 (2007) 507-539
3. Marcellin P., Asselah T., and Boyer N. Treatment of chronic hepatitis B. J Viral Hepat 12 4 (2005) 333-345
4. EASL International Consensus Conference on Hepatitis B. Consensus statement (long version). J Hepatol 39 Suppl 1 (2003) S3-S25
5. Wong D.K.H., Cheung A.M., O'Rourke K., et al. Effect of alfa-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 119 (1993) 312-323
6. Cooksley G., Piratvisuth T., Lee S.D., et al. Peginterferon alfa 2a (40KDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10 (2003) 298-305
7. Janssen H.L., van Zonneveld M., Senturk H., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 9454 (2005) 123-129
8. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 26 (2005) 2682-2695
9. Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 12 (2004) 1206-1217
10. Chan H.L., Leung N.W., Hui A.Y., et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alfa2b and lamivudine with lamivudine alone. Ann Intern Med 142 4 (2005) 240-250
11. Lai C.L., Chien R.W., Leung N.W.Y., et al. Lamivudine Study Group. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 339 (1998) 61-68
12. Dienstag J.L., Schiff E., Wright T., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341 (1999) 1256-1263
13. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 15 (2004) 1521-1531
14. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive hepatitis B. N Engl J Med 348 (2003) 800-807
15. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
16. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352 26 (2005) 2673-2681
17. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 10 (2006) 1011-1020 [erratum in: N Engl J Med. 2006; 354(17):1863]
18. Chang T.T., Gish R.G., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 10 (2006) 1001-1010
19. Thomas H., Foster G., and Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 39 (2003) S93-S98
20. Thomas H.C., Karayiannis P., and Brook G. Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon. J Hepatol 13 (1991) S4-S7
21. Brunetto M.R., Aragon Rodriguez U., and Bonino F. Hepatitis B virus mutant. Intervirology 42 (1999) 69-80
22. Lindsay K.L., Trépo C., Heintges T., et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34 (2001) 395-403
23. Zeuzem S., Feinman S.V., Rasenack J., et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343 (2000) 1666-1672
24. Schalm S.W., Heathcote J., Cianciara J., et al. Lamivudine and alfa interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46 (2000) 562-568
25. Schalm S.W. Combination therapy for chronic hepatitis B. J Hepatol 39 (2003) S146-S150
26. Marcellin P., Bonino F., Lau G.K., et al. Virological and biochemical response in patients with HBeAg-negative CHB treated with peginterferon alfa 2a ± lamivudine: 3 years follow-up results. [abstract 53]. J Hepatol 46 Suppl 1 (2007)